BANK VONTOBEL/CALL/MODERNA/145/0.1/20.09.24 | Market Closed - Boerse Frankfurt Warrants 02:02:24 2024-06-28 pm EDT | ||
| 0.41 EUR | -18.00% |
|
| Current month | -72.48% | ||
| 1 month | -79.80% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 0.41 | -18.00% |
| 24-06-27 | 0.5 | -12.28% |
| 24-06-26 | 0.57 | -45.71% |
| 24-06-25 | 1.05 | +2.94% |
| 24-06-24 | 1.02 | +5.15% |
Real-time Boerse Frankfurt Warrants
Last update June 28, 2024 at 02:02 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VM72XP |
| ISIN | DE000VM72XP5 |
| Date issued | 2024-01-05 |
| Strike | 145 $ |
| Maturity | 2024-09-20 (83 Days) |
| Parity | 10 : 1 |
| Emission price | 0.95 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.24 € |
|---|---|
| Lowest since issue | 0.23 € |
| Spread | 0.02 € |
| Spread % | 4.44% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
- Stock Market
- Warrants
- Warrant
